Previous 10 | Next 10 |
home / stock / mmed:cc / mmed:cc news
Currently, the state of California has the largest number of clinical studies in the country, making up more than 25% of registered clinical trials within the United States. Despite this, numerous studies that involve substances under Schedule I and II haven’t begun, even after obtaining...
A small clinical trial involving military veterans suggests that a psychedelic called ibogaine has the potential to treat traumatic brain injury (TBI) symptoms such as depression and post-traumatic stress disorder (PTSD). The Stanford University study found that the lesser-known psychedelic red...
-- Recently announced statistically significant and clinically meaningful topline Phase 2b data for MM-120 in Generalized Anxiety Disorder (GAD) position for multiple data readouts and catalysts throughout 2024 including initiation of Phase 3 clinical program -- -- Proof-of-Concept study ...
Researchers have developed a potentially “trip-free” psychedelic that could accelerate research efforts to develop psychedelic-based treatments for mental health. The research focused on a critical part of taking hallucinogens — the psychedelic experience — and whe...
Terran Biosciences , a drug developer based in New York, announced recently that it had obtained patent approval for its psychedelic drugs from the U.S. Patent and Trademark Office. The drugs, which have been designed to treat neurological and psychiatric disorders, are based on psilocybin, namel...
– Trial met its primary endpoint with MM-120 demonstrating a statistically significant dose-dependent improvement in HAM-A scores four weeks after a single-dose – – MM-120 100 µg demonstrated a clinically and statistically significant HAM-A reduction of 21.3 poin...
A Canadian study published in the “Journal of Psychoactive Drugs ” has revealed that psilocybin, the main hallucinogenic agent in magic mushrooms, may reduce psychological distress in individuals with childhood trauma. The researchers found a possible association between magic ...
New research has looked into the lasting challenges people face after using psychedelics such as LSD and psilocybin. The researchers’ motivation lay in the increasing interest in and use of psychedelics for therapeutic purposes as well as personal growth. Numerous studies have shown that...
From Nov. 9-11, 2023, hundreds of speakers and exhibitors as well as thousands of attendees congregated at Ice Palace Film Studios to discuss the applications of psychedelics during Wonderland Miami 2023. Unlike last year’s iteration of the conference, which focused on the hallmarks of...
In the recent years, we’ve seen more studies explore the therapeutic benefits of psychedelics, with researchers as well as public figures such as Prince Harry discussing the mental and physical health benefits of these substances. Some countries have even relaxed their laws on psychede...
News, Short Squeeze, Breakout and More Instantly...
Hallucinogenic persistent perception disorder (HPPD) is an intoxication disorder caused by psychedelic drugs that encompasses a range of visual disturbances that occur in different time frames. The disorder also causes extreme anxiety as well as out-of-body sensations and is marked by shame as w...
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (Cboe Canada: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it will present posters describing the...
All Common shares will remain listed on Nasdaq Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (Cboe Canada: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today ...